Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV , and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC 50 s ranging from ~3 to ~68 μM
In Vitro
Cellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination. ?\nGalidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC 50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy . ?\nGalidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Syrian golden hamsters (hamsters infected with YF virus)Dosage: 4 mg/kg of body weight Administration: I.p.; twice daily for 7 days Result: Significantly improved the survival of hamsters infected with YFV.
